MacroGenics | MGNX - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.58B 316M 2026-03
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Biogen USD 554.3M 128.2M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Genmab DKK 208M 60M 2025-12
Geron USD 35.42M 6.24M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
J&J USD 6.03B 719M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 9.71M 1.77M 2026-03
Merck USD 2.67B 180M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Xencor USD 82.12M 65.08M 2026-03